Ircon International Limited (BOM:541956)

Inozyme Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	47,816	21,798	23,381	12,578	4,142
Short-Term Investments	-	4,107	33,697	29,094	43,077	2,283
Cash & Short-Term Investments	51,923	51,923	55,495	52,475	55,654	6,425
Cash Growth	-6.41%	-6.44%	5.75%	-5.71%	766.23%	-76.01%
Accounts Receivable	-	13,283	19,718	18,038	11,994	9,878
Other Receivables	-	1,085	3,278	4,365	2,342	2,227
Receivables	-	14,383	23,005	22,411	14,344	12,115
Inventory	-	908.3	2,374	1,890	2,766	1,207
Prepaid Expenses	-	-	267.1	123.9	105.9	79
Other Current Assets	-	47,501	38,847	34,551	29,658	55,155
Total Current Assets	-	114,715	119,988	111,451	102,528	74,980
Property, Plant & Equipment	-	19,786	7,645	2,139	2,155	2,680
Long-Term Investments	-	8,857	9,897	9,494	9,208	8,340
Other Intangible Assets	-	9,081	9,775	10,778	11,109	11,562
Long-Term Deferred Tax Assets	-	1,445	1,195	1,094	725.3	704.9
Other Long-Term Assets	-	41,326	25,945	20,413	18,734	14,268
Total Assets	-	195,213	174,450	155,374	144,464	112,540
Accounts Payable	-	12,573	8,874	8,554	10,272	7,580
Accrued Expenses	-	-	9,717	10,061	7,548	6,365
Current Portion of Long-Term Debt	-	1,297	1,105	638.8	946	188.4
Current Portion of Leases	-	29.1	7.2	0.9	0.1	0.1
Current Income Taxes Payable	-	158.7	665.6	369.5	180.1	872.1
Current Unearned Revenue	-	-	22,389	28,281	30,216	20,803
Other Current Liabilities	-	58,205	28,471	24,749	23,593	22,022
Total Current Liabilities	-	72,263	71,230	72,654	72,755	57,831
Long-Term Debt	-	41,346	24,567	14,403	13,044	3,121
Long-Term Leases	-	319.2	25.2	4.2	1.5	1.5
Long-Term Unearned Revenue	-	-	9,303	7,464	5,017	3,335
Other Long-Term Liabilities	-	17,665	10,253	8,592	6,968	4,208
Total Liabilities	-	131,593	115,389	103,128	97,796	68,509
Common Stock	-	1,881	1,881	1,881	1,881	940.5
Retained Earnings	-	-	56,575	50,093	44,730	43,093
Comprehensive Income & Other	-	61,383	253.5	141.3	44.8	-1.7
Total Common Equity	63,264	63,264	58,709	52,115	46,656	44,031
Minority Interest	-	356	351.8	131.3	11.3	-
Shareholders' Equity	63,620	63,620	59,061	52,246	46,668	44,031
Total Liabilities & Equity	-	195,213	174,450	155,374	144,464	112,540
Total Debt	42,992	42,992	25,704	15,047	13,992	3,311
Net Cash (Debt)	8,932	8,932	29,791	37,427	41,663	3,114
Net Cash Growth	-70.00%	-70.02%	-20.41%	-10.17%	1237.91%	-88.37%
Net Cash Per Share	9.49	9.49	31.67	39.79	44.30	3.31
Filing Date Shares Outstanding	940.34	941.29	940.52	940.52	940.52	940.52
Total Common Shares Outstanding	940.34	941.29	940.52	940.52	940.52	940.52
Working Capital	-	42,452	48,759	38,797	29,773	17,149
Book Value Per Share	67.21	67.21	62.42	55.41	49.61	46.82
Tangible Book Value	54,183	54,183	48,934	41,337	35,547	32,470
Tangible Book Value Per Share	57.56	57.56	52.03	43.95	37.80	34.52
Land	-	-	441.5	426.9	426.9	795.8
Buildings	-	-	501.6	506.5	501.7	693.8
Machinery	-	-	2,752	2,482	2,223	2,059
Construction In Progress	-	-	5,489	84.7	60.2	31.7
Order Backlog	-	-	272,080	351,950	437,580	346,890

Source: S&P Global Market Intelligence. Standard template. Financial Sources.